Gabapentin

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
US
  • Management of postherpetic neuralgia in adults
Product first approved 1993Outside this platform's coverageFDA label
EU
  • Neurontin and associated names: epileptic syndromes and peripheral neuropathic pain, nationally authorised in EU Member States (SmPC harmonised by an EMA Article 30 referral); no single EU date
EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (72)
Epilepsy
NCT00620555 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-05 – 2010-12 · Epilepsies, Partial
What this study did
Other / comorbidity
NCT06992427 · Alliance for Clinical Trials in Oncology
2025-06-05 – 2031-04-15 · Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
What this study did
NCT05827159 · Yale University
2024-08-17 – 2029-02-01 · Alcohol Use Disorder
What this study did
NCT02219373 · Boston Children's Hospital
2026-06 – 2028-12 · Pediatric Chronic Neuropathic Pain
What this study did
NCT07429734 · Mansoura University
2026-02 – 2027-01 · Overactive Bladder
What this study did
NCT06887998 · Cairo University
2025-03 – 2026-03 · Emergence Agitation
What this study did
NCT05658874 · Jocelyn Fitzgerald
2022-12-06 – 2025-12-30 · Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
What this study did
NCT05921604 · Tanta University
2023-06-30 – 2025-10 · Post Operative Pain
What this study did
NCT05965492 · University of Miami
2024-06-01 – 2025-06-01 · Spinal Disorder
What this study did
NCT05620641 · Tanta University
2022-10-01 – 2025-04-01 · Post Operative Nausea and Vomiting, Sleeve Gastrectomy, Morbid Obesity
What this study did
NCT04144933 · University of Saskatchewan
2021-05-15 – 2024-08-01 · Anesthesia, General Anesthesia, Analgesics, Opioid, Opioid Free Anesthesia, Postoperative Ileus, Colorectal Surgery, Laparoscopic Surgery, Analgesia, Dexmedetomidine, Lidocaine, Ketamine
What this study did
NCT05427474 · Zagazig University
2022-12-01 – 2023-10-31 · Traumatic Brain Injury
What this study did
NCT05100160 · M.D. Anderson Cancer Center
2021-09-15 – 2023-01-03 · Thoracic, Pulmonary Disease
What this study did
NCT04230980 · Weill Medical College of Cornell University
2020-07-28 – 2022-12-16 · Non-obstructive Azoospermia
What this study did
NCT02642484 · Tanta University
2018-12 – 2022-12 · Liver Cirrhosis
What this study did
NCT05539924 · Research Institute of Ophthalmology, Egypt
2022-09-15 – 2022-11-01 · Opioid Use
What this study did
NCT03867240 · Emory University
2019-06 – 2022-09 · Pain, Postoperative, Scoliosis Idiopathic
What this study did
NCT03806530 · Population Health Research Institute
2019-05-01 – 2022-07-19 · End Stage Renal Disease, Restless Legs Syndrome
What this study did
NCT03747562 · University Hospital, Ghent
2019-03-01 – 2022-07-01 · Head Neck Cancer, Radiation Neuropathy, Pain, Neuropathic
What this study did
NCT04429022 · State University of New York at Buffalo
2020-11-24 – 2022-05-31 · Pain, Postoperative
What this study did
NCT05172570 · Indiana University
2021-04-06 – 2022-03-02 · Thoracotomy, Pain, Postoperative
What this study did
NCT04176419 · Case Comprehensive Cancer Center
2020-01-17 – 2021-06-23 · Postoperative Pain Control, Opioid Consumption
What this study did
NCT02987985 · University of Saskatchewan
2017-10-15 – 2020-12-20 · Anesthesia, General Anesthesia, Analgesics, Opioid, Postoperative Complications, Pathologic Processes, Physiologic Effects of Drugs, Narcotics, Analgesics, Sleep Disordered Breathing, Obstructive Sleep Apnea of Child, Tonsillectomy, Respiratory Depression, Dexmedetomidine, Ketamine, Lidocaine, Gabapentin, Pulse Oximetry
What this study did
NCT03269344 · Henry Ford Health System
2017-06-05 – 2020-12-09 · Oropharynx Cancer
What this study did
NCT03255330 · Masaryk University
2017-10 – 2020-08 · Chronic Pain Due to Trauma, Spinal Cord Injuries
What this study did
NCT03682367 · University of California, Davis
2018-12-01 – 2020-04-06 · Cancer of Head and Neck, Narcotic Use
What this study did
NCT02480114 · Vanderbilt-Ingram Cancer Center
2015-07 – 2020-01 · Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
What this study did
NCT02722603 · Pharmaceutical Research Management srl
2018-09-12 – 2019-06-18 · Chronic Pain
What this study did
NCT03158376 · University Hospital, Lille
2015-09 – 2019-05-24 · Postoperative Pain, Chronic Pain
What this study did
NCT02999724 · Mount Sinai Hospital, Canada
2017-01 – 2018-01 · Pelvic Organ Prolapse
What this study did
NCT03186443 · Second Affiliated Hospital of Guangzhou Medical University
2017-10-01 – 2017-10-01 · Herpetic Neuralgia
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00312260 · The Hospital for Sick Children
2006-04 – 2017-03-02 · Pain
What this study did
NCT02918760 · Ain Shams University
2016-03 – 2016-12 · Pelvic Pain
What this study did
NCT01067144 · Stanford University
2010-05 – 2016-07 · Pain, Breast Cancer, Lung Cancer
What this study did
NCT02384187 · Cairo University
2015-01 – 2015-08 · Post Operative Nausea and Vomiting (PONV), Adenotonsillectomy
What this study did
NCT00880191 · Alliance for Clinical Trials in Oncology
2009-04 – 2015-05 · Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT03274167 · Chulalongkorn University
2012-01 – 2014-12 · Alcohol Drinking, Heavy Drinking
What this study did
NCT00221338 · University of California, San Francisco
2006-01 – 2014-07 · Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay
What this study did
NCT01888497 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2013-07-29 – 2013-12-14 · Healthy
What this study did
NCT01116583 · University of Aarhus
2011-05 – 2013-11 · Pain, Postoperative
What this study did
NCT01052896 · 59th Medical Wing
2010-03 – 2012-08-28 · Functional Dyspepsia
What this study did
NCT02120703 · Aga Khan University
2011-02 – 2011-10 · Intervertebral Disc Prolapse
What this study did
NCT01080300 · Depomed
2010-08 – 2011-09 · Hot Flashes
What this study did
NCT00934193 · University of Kansas Medical Center
2009-07 – 2011-06 · Post-thoracotomy Pain
What this study did
NCT01052844 · Faculdade de Medicina do ABC
2009-01 – 2010-07 · Vomiting, Cisplatin Adverse Reaction
What this study did
NCT01107574 · Good Samaritan Regional Medical Center, Oregon
2004-04 – 2010-04 · Fibromyalgia
What this study did
Phase 2/3 (20)
Other / comorbidity
NCT04724252 · University of California, Davis
2021-08-23 – 2027-12-31 · Pain, Postoperative
What this study did
NCT07047040 · Assiut University
2025-08-15 – 2027-12-30 · Pain, Postoperative, Osteoarthritis, Knee
What this study did
NCT07916116 · Assiut University
2026-03-01 – 2027-05-01 · Postdural Puncture Headache (PDPH)
What this study did
NCT07625410 · Rehman Medical Institute - RMI
2023-05-01 – 2024-05-01 · Effectiveness of Drugs Was Compared for Treating Trigeminal Neuralgia, Pain, Pain Management
What this study did
NCT04939987 · Wake Forest University Health Sciences
2022-08 – 2022-10 · Radical Prostatectomies
What this study did
NCT02543944 · University of Arkansas
2016-02 – 2021-05-31 · Drug Dependence
What this study did
NCT03566394 · British Columbia Cancer Agency
2018-07-02 – 2020-06-30 · Invasive Breast Cancer, Chemotherapeutic Toxicity, Myalgia, Arthralgia
What this study did
NCT03825809 · Henry Ford Health System
2019-01-22 – 2020-05-20 · Narcotic Use
What this study did
NCT03818932 · Henry Ford Health System
2019-01-22 – 2020-05-20 · Anterior Cruciate Ligament Injury
What this study did
NCT03496389 · Hospital Authority, Hong Kong
2018-07-01 – 2019-08-01 · Muscle Weakness, Anterior Cruciate Ligament Rupture
What this study did
NCT02355886 · University of Washington
2015-04-22 – 2019-02-28 · Bladder Carcinoma
What this study did
NCT03172234 · Ghada Mohammed AboelFadl
2017-06-15 – 2018-05-15 · Effect of Laryngoscopy and Tracheal Intubation
What this study did
NCT02525848 · Assiut University
2015-08 – 2016-03 · Postoperative Nausea and Vomiting
What this study did
NCT02099006 · University of Rochester
2013-11 – 2015-06 · Female Genital Diseases
What this study did
NCT01486706 · Michael E. Chua
2010-10 – 2015-01 · Urinary Urgency, Urinary Frequency, Nocturia, Incontinence, Detrusor Uninhibited Activity, Quality of Life
What this study did
NCT01141049 · New York State Psychiatric Institute
2010-08 – 2012-12 · Alcohol Dependence
What this study did
NCT00735124 · University of Oklahoma
2008-11-06 – 2009-09 · Pain, Analgesia, Hernia, Inguinal
What this study did
NCT00262639 · Medical University of South Carolina
2005-12 – 2008-03 · Alcohol Dependence
What this study did
NCT00317850 · Washington University School of Medicine
2004-04 – 2006-02 · Tinnitus
What this study did
NCT00057278 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2003-03 – 2006-01 · Fibromyalgia
What this study did
Phase 2 (54)
Other / comorbidity
NCT05443555 · Boston Medical Center
2023-11-20 – 2027-06 · HIV, Heavy Drinking
What this study did
NCT05064319 · Medical University of South Carolina
2022-02-24 – 2026-07-31 · Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
What this study did
NCT04619862 · University of British Columbia
2021-05-15 – 2026-04-30 · Pain, Neuropathic Pain, Irritability
What this study did
NCT04429347 · University of California, San Diego
2020-07-29 – 2024-12-01 · Insomnia Due to Medical Condition, Chronic Pain
What this study did
NCT05184192 · Washington University School of Medicine
2022-01-10 – 2023-08-29 · COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
What this study did
NCT04766229 · University College Dublin
2021-06-21 – 2022-11-30 · Menopause, Cancer, Insomnia
What this study did
NCT03220776 · Medical University of South Carolina
2017-08-07 – 2022-11-21 · Alcohol Use Disorder, Bipolar Disorder
What this study did
NCT03423264 · University of Chicago
2018-01-22 – 2022-11-08 · Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
What this study did
NCT03205423 · New York State Psychiatric Institute
2017-08-01 – 2021-12-30 · Opioid-use Disorder, Alcohol Use Disorder
What this study did
NCT04052139 · Boston Medical Center
2021-01-25 – 2021-12-15 · Chronic Pain, Alcohol Use, Unspecified, HIV Infections
What this study did
NCT03574792 · Roswell Park Cancer Institute
2018-05-03 – 2021-11-11 · Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
What this study did
NCT03084536 · Washington University School of Medicine
2017-06-07 – 2021-02-25 · Breast Cancer, Breast Cancer Female, Cancer of Breast
What this study did
NCT03818919 · Henry Ford Health System
2019-01-22 – 2020-12-31 · Rotator Cuff Tear
What this study did
NCT03749642 · Aziende Chimiche Riunite Angelini Francesco S.p.A
2018-11-22 – 2020-06-06 · Painful Diabetic Neuropathy
What this study did
NCT03708237 · University of Alberta
2019-02-19 – 2019-12-11 · Restless Legs Syndrome, End Stage Renal Disease
What this study did
NCT02163434 · State University of New York at Buffalo
2014-06 – 2019-11 · Hyperemesis Gravidarum
What this study did
NCT03275012 · Pharmaceutical Research Management srl
2017-04-04 – 2019-10-21 · Chronic Pain
What this study did
NCT03679013 · Inova Health Care Services
2019-04-19 – 2019-07-12 · Pain, Postoperative
What this study did
NCT03334721 · Medical University of South Carolina
2017-10-01 – 2019-07-01 · Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
What this study did
NCT02349477 · Medical University of South Carolina
2014-11 – 2018-08-27 · Alcohol Use Disorder, Alcohol Withdrawal
What this study did
NCT02725710 · Duke University
2016-08 – 2018-06-14 · Other Abortion, Spontaneous Abortion
What this study did
NCT01954927 · St. Jude Children's Research Hospital
2013-10-07 – 2018-01-03 · Sickle Cell Disease
What this study did
NCT01506453 · St. Jude Children's Research Hospital
2012-01-24 – 2018-01-02 · Acute Lymphoblastic Leukemia, Neuropathy, Neuropathic Pain
What this study did
NCT01675960 · Gillette Children's Specialty Healthcare
2012-04 – 2017-07 · Neurologically Impaired, Irritable Mood, Signs and Symptoms, Digestive, Sleeplessness, Chronic Pain
What this study did
NCT03023501 · King Saud University
2014-03 – 2017-01 · Postoperative Complications
What this study did
NCT00974376 · The Scripps Research Institute
2009-11-04 – 2016-05-19 · Cannabis Dependence, Cannabis Withdrawal, Cognitive Deficits
What this study did
NCT01893632 · New York State Psychiatric Institute
2013-07 – 2016-04-01 · Benzodiazepine Dependence
What this study did
NCT02252926 · Hvidovre University Hospital
2014-09 – 2015-12 · Mucositis
What this study did
NCT01588314 · University of Minnesota
2012-04 – 2014-06 · Fabry Disease, Neuropathic Pain
What this study did
NCT01533753 · University of Wisconsin, Madison
2012-02 – 2014-05 · Prostate Cancer
What this study did
NCT01005108 · Abramson Cancer Center at Penn Medicine
2009-01 – 2014-01-31 · Hot Flashes
What this study did
NCT01744444 · Hospices Civils de Lyon
2012-11 – 2013-07 · Pendular Nystagmus Patients With Multiple Sclerosis
What this study did
NCT01262092 · University of Arkansas
2010-10 – 2012-01 · Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
What this study did
NCT00967707 · Uppsala University
2009-08 – 2011-09 · Post-traumatic Neuropathic Pain
What this study did
NCT00420771 · New York State Psychiatric Institute
2007-01 – 2011-01 · Benzodiazepine Dependence, Opioid Dependence
What this study did
NCT00414466 · MedtronicNeuro
2006-12 – 2010-08 · Chronic Intractable Pain
What this study did
NCT01210079 · University of California, Los Angeles
2002-09 – 2010-05 · Opioid-Induced Hyperalgesia
What this study did
NCT01014520 · Tabriz University
2009-05 – 2010-03 · Herniated Disc, Intervertebral Disc Displacement
What this study did
NCT00391716 · The Scripps Research Institute
2004-02 – 2010-02 · Alcoholism, Alcohol Dependence
What this study did
NCT00108550 · US Department of Veterans Affairs
2004-10 – 2009-09 · Chronic Low Back Pain
What this study did
NCT00617461 · XenoPort, Inc.
2008-03 – 2009-07 · Neuralgia, Postherpetic
What this study did
NCT00654953 · University of Arkansas
2006-01 – 2009-05 · Cocaine Dependence, Depressive Symptoms
What this study did
NCT00578552 · Mayo Clinic
2007-10 – 2009-05 · Cigarette Smoking, Tobacco Use
What this study did
NCT00555776 · Islamic Azad University of Mashhad
2007-01 – 2008-10 · Subjective Tinnitus
What this study did
NCT00395044 · The Scripps Research Institute
2006-08 – 2008-07 · Cannabis Dependence
What this study did
NCT00475904 · EpiCept Corporation
2007-07 – 2008-06 · Post Herpetic Neuralgia, PHN, Neuropathy, Nerve Pain
What this study did
NCT00250744 · New Mexico Cancer Research Alliance
2004-12 – 2007-09 · Cancer
What this study did
NCT00712439 · Depomed
2006-04 – 2006-12 · Diabetic Peripheral Neuropathy
What this study did
Phase 1/2 (8)
Other / comorbidity
NCT07846020 · University of Maryland, Baltimore
2027-01-15 – 2032-04-01 · Chronic Lower Back Pain (CLBP)
What this study did
NCT05156060 · Natalie Lockney
2022-01-24 – 2026-12-31 · Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma
What this study did
NCT05664464 · University of Zurich
2023-01-01 – 2026-12 · Glioblastoma
What this study did
NCT06705101 · Liaquat National Hospital & Medical College
2024-12-15 – 2025-07-16 · Elective Surgical Patients, Blood Pressure
What this study did
NCT03750773 · Indiana University
2019-07-02 – 2020-04 · Postoperative Pain
What this study did
NCT04434430 · Universitas Indonesia
2019-11-11 – 2020-02-29 · Non-obstetric Lower Abdominal Surgery
What this study did
NCT02557945 · New York State Psychiatric Institute
2015-08-01 – 2016-06-12 · Clinical High Risk for Psychosis
What this study did
NCT01200641 · Qazvin University Of Medical Sciences
2010-09 – 2011-01 · Anxiety, Pain
What this study did
Phase 1 (37)
Epilepsy
NCT01821235 · University Hospital, Ghent
2013-04 – 2013-11 · Epilepsy and Neuropathic Pain
What this study did
NCT01738893 · GlaxoSmithKline
2011-01-14 – 2011-01-22 · Epilepsy
What this study did
Other / comorbidity
NCT03498261 · Ohio State University
2018-01-30 – 2027-12-30 · Pain, Postoperative, Opioid Use
What this study did
NCT06212830 · Assaf-Harofeh Medical Center
2024-02 – 2025-08 · Provide Evidence-based Recommendations for Clinicians to Optimize Pain Control After CXL
What this study did
NCT06752486 · Research Institute of Ophthalmology, Egypt
2024-12-01 – 2025-06 · Pain After Photorefractive Keratectomy, VAS Will be Used to Assess Pain Postoperative
What this study did
NCT04631510 · Tufts Medical Center
2020-12-01 – 2025-05-30 · Intensive Care Unit Sleep Disruption
What this study did
NCT05609682 · University of Oklahoma
2022-11-29 – 2024-05-29 · Post Operative Pain
What this study did
NCT05301205 · Cairo University
2021-06-25 – 2023-07-30 · Gabapentin
What this study did
NCT05659810 · Ain Shams University
2022-12-26 – 2023-04-10 · Prolongation of Spinal Anesthesia
What this study did
NCT05533684 · Minia University
2022-09-01 – 2022-12-31 · Pain, Postoperative
What this study did
NCT03589898 · University of Massachusetts, Worcester
2017-09-14 – 2022-08-31 · Autism Spectrum Disorder
What this study did
NCT04802967 · Dompé Farmaceutici S.p.A
2021-02-08 – 2022-04-25 · No Condition
What this study did
NCT03346668 · University of Minnesota
2016-01-28 – 2021-10-11 · Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
What this study did
NCT04622618 · Ain Shams University
2020-09-15 – 2021-02-15 · Nausea, Postoperative, Vomiting, Postoperative, Pain, Postoperative
What this study did
NCT03820193 · Henry Ford Health System
2019-01-22 – 2021-01-20 · Meniscus Disorder, Narcotic Use
What this study did
NCT04620720 · Combined Military Hospital, Pakistan
2020-08-01 – 2020-12-01 · Post Operative Pain
What this study did
NCT02856750 · Denver Health and Hospital Authority
2016-10 – 2018-10-23 · Acute Pain
What this study did
NCT03088306 · Johns Hopkins University
2017-07-01 – 2018-08-31 · Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
What this study did
NCT02531906 · Roswell Park Cancer Institute
2015-04-24 – 2018-06-14 · Head and Neck Squamous Cell Carcinoma, Pain, Stomatitis
What this study did
NCT04292171 · University of Nevada, Las Vegas
2017-05-01 – 2018-03-30 · Pain Control
What this study did
NCT02490345 · Indiana University
2015-10 – 2017-06-29 · Drug Usage
What this study did
NCT02056899 · State University of New York at Buffalo
2013-06 – 2015-08 · Preterm Labor, Premature Birth
What this study did
NCT01441531 · Baylor College of Medicine
2012-01 – 2014-06 · Tourniquet-induced Pain, Tourniquet-induced Hypertension
What this study did
NCT01421264 · State University of New York at Buffalo
2011-08 – 2013-06 · Insomnia
What this study did
NCT01485185 · GlaxoSmithKline
2011-10-11 – 2012-07-03 · Pain, Neuropathic
What this study did
NCT01092520 · The Hospital for Sick Children
2009-07 – 2011-07 · Pruritus
What this study did
NCT00593463 · University of Arkansas
2006-09 – 2010-05 · Drug Dependence
What this study did
NCT00987779 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-10 – 2009-10 · Healthy
What this study did
NCT00833391 · XenoPort, Inc.
2009-01 – 2009-03 · Pharmacokinetics, Healthy Volunteer
What this study did
NCT01119222 · Pfizer
2008-07 – 2008-10 · Healthy
What this study did
NCT00865059 · Actavis Inc.
2001-02 – 2001-03 · Healthy
What this study did
NCT00865423 · Actavis Inc.
2001-02 – 2001-03 · Healthy
What this study did
NCT00865631 · Actavis Inc.
1999-06 – 1999-06 · Healthy
What this study did
NCT00864760 · Actavis Inc.
1999-06 – 1999-06 · Healthy
What this study did
NCT00864305 · Actavis Inc.
1997-12 – 1998-01 · Healthy
What this study did
NCT00864058 · Actavis Inc.
1998-01 – 1998-01 · Healthy
What this study did
Phase 4 (113)
Epilepsy
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT02977208 · São Paulo State University
2016-09 – 2018-02 · Epilepsy, Chronic Pain
What this study did
NCT00537940 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-02 – 2013-07 · Epilepsy, Partial Seizure Disorder, Epilepsies, Partial, Complex Partial Seizure Disorder
What this study did
Other / comorbidity
NCT07158476 · St. Louis University
2025-10-21 – 2031-09 · ACL Surgery, Pain Management
What this study did
NCT07750639 · AdventHealth
2024-08-01 – 2027-12-30 · Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
What this study did
NCT07308717 · Memorial Sloan Kettering Cancer Center
2025-12-16 – 2027-12-16 · Breast Cancer
What this study did
NCT07840183 · Northwestern University
2026-09-25 – 2027-11 · Ventral Hernia, Ventral Hernia Repair, Postoperative Pain
What this study did
NCT07859839 · Post Graduate Institute of Medical Education and Research, Chandigarh
2026-10-07 – 2027-07-31 · Interstitial Lung Disease
What this study did
NCT06997016 · Baylor Research Institute
2025-05-05 – 2027-06 · Postoperative Pain
What this study did
NCT06379425 · Northwell Health
2024-03-01 – 2027-03-01 · Pain, Postoperative, Postoperative Pain, Acute
What this study did
NCT04860141 · Loma Linda University
2021-06-16 – 2026-12 · Dental Pain and Sensation Disorder, Pain, Postoperative
What this study did
NCT07777965 · Viatris Inc.
2026-06-18 – 2026-08-31 · Healthy Non-dependent, Recreational Sedative Users
What this study did
NCT05690282 · University of California, San Diego
2021-05-17 – 2026-05-17 · Post-operative Pain
What this study did
NCT05302999 · MetroHealth Medical Center
2022-03-14 – 2026-03-31 · Spinal Cord Injuries
What this study did
NCT05063656 · David Cochran
2022-02-04 – 2025-12-31 · Autism Spectrum Disorder
What this study did
NCT06254183 · Tanta University
2024-12-01 – 2025-11-30 · Acute Kidney Injury, Obesity
What this study did
NCT05076110 · Mayo Clinic
2022-04-07 – 2025-10-25 · Hip Arthroscopy
What this study did
NCT04240626 · University of California, Davis
2021-01-20 – 2025-06-24 · Obesity, Morbid, Surgery, Bariatric Surgery Candidate
What this study did
NCT06781489 · Universidad Europea de Madrid
2025-02-19 – 2025-03-29 · Carpal Tunnel Syndrome
What this study did
NCT06778798 · Universidad Europea de Madrid
2025-02-19 – 2025-03-25 · Carpal Tunnel Syndrome
What this study did
NCT05658887 · Joseph Kowalski
2023-01-01 – 2024-12-31 · Pelvic Organ Prolapse, Perioperative/Postoperative Complications
What this study did
NCT04705480 · CAMC Health System
2021-04-12 – 2024-12-13 · Analgesics, Gabapentin, Injuries, Narcotics, Pain, Trauma
What this study did
NCT04865042 · Lille Catholic University
2022-02-02 – 2024-12-09 · Radiculopathy of Lumbosacral Spine Due to Disc Disorder
What this study did
NCT06346522 · Ain Shams University
2024-04-10 – 2024-09-20 · Catheter-related Bladder Discomfort (CRBD)
What this study did
NCT05800847 · Hughston Clinic
2023-04 – 2024-07 · Rotator Cuff Tears
What this study did
NCT05494385 · Indiana University
2021-07-27 – 2023-07-05 · Postoperative Pain
What this study did
NCT03859024 · University of Alabama at Birmingham
2019-03-22 – 2023-06-30 · Pain, Postoperative, Urethral Stricture
What this study did
NCT04246697 · University of Kansas Medical Center
2019-11-01 – 2023-05-01 · Head and Neck Cancer, Analgesia
What this study did
NCT05626998 · Ain Shams University
2022-11-01 – 2023-04-30 · Anesthesia
What this study did
NCT04570436 · Viatris Specialty LLC
2021-03-29 – 2022-11-10 · Abuse Potential
What this study did
NCT05750875 · King Edward Medical University
2022-05-01 – 2022-10-31 · Pruritus, Uremia, Chronic Kidney Diseases
What this study did
NCT05324761 · Al-Kindy College of Medicine
2022-04-25 – 2022-06-30 · Failed Back Surgery Syndrome
What this study did
NCT02693821 · Hospital Italiano de Buenos Aires
2015-12 – 2022-06 · Pain, Postoperative
What this study did
NCT05413902 · University of Puerto Rico
2021-04-05 – 2022-03-23 · Pain Management, Posterior Spinal Fusion
What this study did
NCT05296759 · Alexandria University
2021-02-01 – 2022-03-08 · Diabetic Neuropathies
What this study did
NCT02685735 · Wake Forest University Health Sciences
2016-06-02 – 2022-02-09 · Pain, Total Knee Replacement, Total Hip Replacement
What this study did
NCT05319756 · Viatris Specialty LLC
2021-04-30 – 2021-12-31 · Abuse Potential
What this study did
NCT03151746 · Northwestern University
2018-01-14 – 2021-12-02 · Anesthesia, Urethral Obstruction
What this study did
NCT03121963 · University of Alabama at Birmingham
2017-11-10 – 2021-11-06 · Pain Management
What this study did
NCT02957097 · Massachusetts General Hospital
2019-09 – 2021-07 · Pain, Postoperative, Acute Pain, Facial Pain
What this study did
NCT05024825 · Albany Medical College
2017-08-04 – 2021-05-19 · Pain, Postoperative
What this study did
NCT03472521 · Stanford University
2018-09-17 – 2021-04-10 · Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
What this study did
NCT03012815 · Mayo Clinic
2017-02-01 – 2021-03-01 · Alcohol Withdrawal Syndrome
What this study did
NCT03393702 · National Institute for Tuberculosis and Lung Diseases, Poland
2017-05-09 – 2020-12-03 · Pain, Postoperative, Surgery, Thoracic
What this study did
NCT03335436 · Vanderbilt University Medical Center
2018-04-01 – 2020-12 · Cesarean Delivery, Pain Management
What this study did
NCT03123861 · University of North Carolina, Chapel Hill
2017-06-01 – 2020-07-25 · Pelvic Organ Prolapse
What this study did
NCT03635905 · Medstar Health Research Institute
2017-05-26 – 2020-05-20 · Pain
What this study did
NCT04653415 · Jagiellonian University
2019-06-01 – 2020-05-01 · Arthroplasty Complications, Knee Osteoarthritis, Pain, Postoperative, Perioperative Complication
What this study did
Early phase / not applicable (80)
Other / comorbidity
NCT07941726 · University Hospital, Toulouse
2026-11 – 2028-05 · Stroke, Brain Plasticity, GABAergic Modulation, Motor Learning, Spasticity, Anxiety, Neuropathic Pain
What this study did
NCT07169006 · Ain Shams University
2026-01-01 – 2026-12-01 · Bariatric Surgery Analgesia
What this study did
NCT07019103 · Haroon Muhammad Khalil
2025-03-02 – 2026-11-15 · Pain Management, Analgesia, Postoperative
What this study did
NCT07515456 · Tanta University
2024-12-01 – 2026-11-01 · Theophylline, Sumatriptan, Gabapentin, Post-Dural Puncture Headache
What this study did
NCT06565546 · University of Florida
2025-01-29 – 2026-10-31 · Ventral Hernia
What this study did
NCT07804784 · Shaukat Khanum Memorial Cancer Hospital & Research Centre
2026-01-01 – 2026-06-30 · Breast Cancer Surgery Pain
What this study did
NCT07907406 · Lahore General Hospital
2026-01-01 – 2026-06-30 · Guillain-Barré Syndrome, Neuropathic Pain
What this study did
NCT07131527 · Sohag University
2025-07-14 – 2026-01-20 · Cholecystitis, Chronic
What this study did
NCT07389551 · Muhammad Aamir Latif
2025-07-01 – 2025-12-31 · Orthopedic Surgery
What this study did
NCT07000201 · Cairo University
2025-09-15 – 2025-12-30 · Anxiety, Anxiety Disorder (Panic Disorder or GAD)
What this study did
NCT06893172 · University of Medicine and Pharmacy at Ho Chi Minh City
2025-04-01 – 2025-08-29 · Postherpetic Neuralgia ( PHN )
What this study did
NCT06798662 · Xiaguang Duan
2025-02-01 – 2025-06-10 · Herpes Zoster (HZ)
What this study did
NCT07191587 · National Cancer Institute, Egypt
2024-12-01 – 2025-05-30 · Peripheral Neuropathy, Chemotherapy-induced, Disease Management
What this study did
NCT05997355 · University of Puerto Rico
2023-09-01 – 2024-07-31 · Postoperative Pain, Opioid Use
What this study did
NCT07297888 · Shri Guru Ram Rai Institute of Medical and Health Sciences
2022-07-20 – 2024-03-20 · Pain
What this study did
NCT05384210 · Mansoura University
2022-06 – 2023-11 · Fibromyalgia
What this study did
NCT06112223 · Tanta University
2023-04-01 – 2023-09-01 · Gabapentin, Tramadol, Postoperative Pain, Knee Arthroscopy, Spinal Anesthesia
What this study did
NCT06190132 · Ain Shams University
2023-04-01 – 2023-07-30 · Uremic Pruritus in Hemodialysis Patients
What this study did
NCT07267182 · Muhammad Aamir Latif
2022-08-01 – 2023-02-28 · Postoperative Pain
What this study did
NCT04818450 · Mahidol University
2021-04-19 – 2022-07-31 · Sleep Deprivation, Critically Ill
What this study did
NCT06354478 · National Cancer Institute, Egypt
2021-01-01 – 2022-07-01 · Breast Cancer, Pain, Postoperative, Pain, Acute
What this study did
NCT01678586 · Massachusetts General Hospital
2012-12 – 2021-12 · Pain
What this study did
NCT04976374 · National Cancer Institute, Egypt
2021-05-25 – 2021-11-25 · Analgesia
What this study did
NCT05037994 · Zagazig University
2021-04-01 – 2021-10-30 · Pain, Shoulder
What this study did
NCT03351439 · Western University, Canada
2018-04-06 – 2021-09-30 · Hip Pain Chronic
What this study did
NCT04491786 · Gia Dinh People Hospital
2020-08-01 – 2021-05-31 · Spinal Fusion
What this study did
NCT04148846 · University of Sao Paulo General Hospital
2019-09-20 – 2021-02-15 · Headache, Post-Dural Puncture
What this study did
NCT04700592 · University Tunis El Manar
2020-10-02 – 2021-02-02 · Chronic Pain Following Surgical Procedure for Cancer
What this study did
NCT03120962 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2017-05 – 2020-11 · Herpes Zoster, Post-herpetic Neuralgia
What this study did
NCT07644065 · Plovdiv Medical University
2017-10-16 – 2020-09-30 · Impacted Third Molar, Postoperative Pain, Neuroinflammation, Anxiety
What this study did
NCT03826615 · Seoul National University Hospital
2019-02-01 – 2020-01-03 · Hyperalgesia, Cataract Bilateral Nos
What this study did
NCT03521167 · Shanghai Zhongshan Hospital
2018-05-01 – 2019-12-30 · Cardiac Surgery
What this study did
NCT03859102 · James Cook University Hospital
2018-12-17 – 2019-11-29 · Cardiac Surgery, Coronary Artery Disease, Aortic Valve Disease, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Root Dilatation
What this study did
NCT04003350 · Rothman Institute Orthopaedics
2017-12-21 – 2019-03-15 · Osteo Arthritis Knee
What this study did
NCT03202459 · Faculdade de Ciências Médicas da Santa Casa de São Paulo
2017-03-02 – 2018-01-31 · Postoperative Complications, Postoperative Nausea and Vomiting
What this study did
NCT03347916 · Kuwait Specialized Eye Center
2017-01-05 – 2017-11-30 · Emergence Agitation After Desflurane Anesthesia
What this study did
NCT04345432 · Medstar Health Research Institute
2014-01 – 2017-09 · Postural Orthostatic Tachycardia Syndrome
What this study did
NCT02605187 · Stanford University
2015-11 – 2017-05-22 · Postoperative Pain
What this study did
NCT02402543 · University of Vermont
2014-06 – 2017-05 · Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
What this study did
NCT02617121 · Hallym University Medical Center
2015-11 – 2016-10 · Postoperative Nausea and Vomiting
What this study did
NCT02202707 · Beth Israel Deaconess Medical Center
2014-05 – 2016-06 · Vasomotor Symptoms, Cardiovascular Health
What this study did
NCT02306278 · Capital Medical University
2014-12-14 – 2016-06 · Cerebral Tumor
What this study did
NCT01301001 · University of Tennessee
2012-08 – 2016-01 · Vulvodynia
What this study did
NCT01707420 · University of Colorado, Denver
2012-08 – 2015-12 · Post Operative Pain Management in Children With Tonsillectomy/Adenoidectomy
What this study did
NCT02040532 · Massachusetts General Hospital
2014-01 – 2015-08 · Menopause, Hot Flashes, Vasomotor Disturbance
What this study did
NCT01623271 · Massachusetts General Hospital
2013-05 – 2014-06 · Complex Regional Pain Syndrome I (CRPS I)
What this study did
NCT01489631 · St. Antonius Hospital
2013-03 – 2014-04 · Total Knee Arthroplasty
What this study did
NCT01848119 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2013-05 – 2014-02 · Pain
What this study did
NCT02052414 · The Center for Clinical Research, Winston-Salem, NC
2012-07 – 2013-11 · Fibromyalgia
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Other / comorbidity
NCT00711529 · Women and Infants Hospital of Rhode Island
2008-07 – 2011-06 · Breast Cancer, Hot Flashes
What this study did
NCT01263132 · Merck KGaA, Darmstadt, Germany
2008-02 – 2010-02 · Diabetic Neuropathies, Polyneuropathies
What this study did
Phase 2 (2)
Other / comorbidity
NCT05494437 · PleoPharma, Inc.
2022-10-27 – 2023-08-21 · Cannabis Withdrawal
What this study did
NCT00755508 · Takeda
2005-11 – 2006-09 · Sleep Initiation and Maintenance Disorders
What this study did
Phase 1 (2)
Other / comorbidity
NCT04613024 · Stanford University
2025-07-01 – 2027-07-01 · Weight Loss, Pain, Postoperative
What this study did
NCT06776445 · First Affiliated Hospital of Chongqing Medical University
2024-01-05 – 2025-07-31 · Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)
What this study did
Phase 4 (8)
Other / comorbidity
NCT06466421 · Tanta University
2024-07-01 – 2024-12-20 · Uremic Pruritus, Chronic Kidney Disease-associated Pruritus, Hemodialysis, End-stage Renal Disease, Renal Replacement Therapy, ESRD
What this study did
NCT05875610 · Mit Ghamr Oncology Center
2023-05-01 – 2023-12-01 · Peripheral Neuropathy Due to Chemotherapy
What this study did
NCT04285281 · Universidad Europea de Madrid
2020-04-01 – 2020-08-10 · Carpal Tunnel Syndrome
What this study did
NCT04025203 · Francisco Unda Solano
2019-08-01 – 2019-11-30 · Carpal Tunnel Syndrome
What this study did
NCT03619785 · Andrew A Herring
2018-11-06 – 2019-08-31 · Rib Fractures, Rib Fracture Multiple
What this study did
NCT02074267 · Nang Kuang Pharmaceutical Co., Ltd.
2009-03 – 2011-09 · Neuropathy, Pain
What this study did
NCT00634543 · Janssen Korea, Ltd., Korea
2006-12 – 2008-10 · Diabetic Neuropathy
What this study did
NCT00904202 · Endo USA Inc., a Keenova Therapeutics Company
2003-01 – 2003-06 · Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
What this study did
Early phase / not applicable (6)
Other / comorbidity
NCT06301061 · Federico II University
2024-04-01 – 2026-04-01 · Pain, Chronic, Lumbosacral Radiculopathy, Radicular; Neuropathic
What this study did
NCT05699876 · All India Institute of Medical Sciences
2023-01-15 – 2023-11-30 · Anxiety, Preoperarative
What this study did
NCT05392361 · Yonsei University
2022-06-09 – 2023-03-24 · Lumbar Spinal Stenosis With Nocturnal Calf Cramps
What this study did
NCT02737826 · Medical University of South Carolina
2016-05 – 2021-01-13 · Chronic Pain, Opioid Pain Medication
What this study did
NCT01495923 · Johns Hopkins University
2011-12 – 2014-09 · Sciatica, Radiculopathy
What this study did
NCT01144923 · Johns Hopkins University
2010-06 – 2013-11 · Cervical Radiculopathy
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Other / comorbidity
NCT01364298 · Merck KGaA, Darmstadt, Germany
2011-04 – 2012-07 · Diabetic Peripheral Neuropathic Pain
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (4)
Epilepsy
NCT00855738 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2009-06 · Focal Epilepsy
What this study did
Other / comorbidity
NCT05820685 · The University of Texas Health Science Center, Houston
2023-07-27 – 2024-04-29 · Trauma Injury
What this study did
NCT04523935 · Sathbhavana Brain Clinic
2005-12-07 – 2020-08-04 · Cerebral Palsy, Excessive Crying, Pain
What this study did
NCT02987920 · University of Southern California
2017-01 – 2018-01 · Pain, Postoperative
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT07593313 · Nanchong Central Hospital
2024-01-01 – 2029-08-01 · Central Post-Stroke Pain
What this study did
NCT07348952 · Cairo University
2023-09-01 – 2025-03-01 · Transcutaneous Electrical Nerve Stimulation, Pudendal Neuralgia, Post Prostatectomy
What this study did
NCT03149432 · Centre d'Investigation Clinique et Technologique 805
2017-02-22 – 2019-08-31 · Amputation, Phantom Pain Following Amputation of Lower Limb
What this study did

Competitive landscape

Other α2δ subunit of voltage-gated calcium channels drugs

Pregabalin. Compare all 2 α2δ subunit of voltage-gated calcium channels drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gabapentin: this drugApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 12 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gabapentin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Dental Pain and Sensation Disorder, Pain, PostoperativeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04860141 · CT.gov ↗
What to watch
2027 (11)
January 2027 (2)
Phase 4Pain, Postoperative, Postoperative Pain, AcuteRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT06379425 · CT.gov ↗
What to watch
Phase 4HealthyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT07813026 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2/3Postdural Puncture Headache (PDPH)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-01 · NCT07916116 · CT.gov ↗
What to watch
June 2027 (2)
Phase 4Postoperative PainEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT06997016 · CT.gov ↗
What to watch
Phase 4Interstitial Lung DiseaseNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07859839 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Ventral Hernia, Ventral Hernia Repair, Postoperative PainRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT07840183 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2/3Pain, Postoperative, Osteoarthritis, KneeNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-30 · NCT07047040 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid ConsumptionEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-11-30 · NCT07750639 · CT.gov ↗
What to watch
December 2027 (3)
Phase 4Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-16 · NCT07308717 · CT.gov ↗
What to watch
Phase 1Pain, Postoperative, Opioid UseActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT03498261 · CT.gov ↗
What to watch
Phase 2/3Pain, PostoperativeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT04724252 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
Early phase / not applicableStroke, Brain Plasticity, GABAergic Modulation, Motor Learning, Spasticity, Anxiety, Neuropathic PainNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05 · NCT07941726 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Alcohol Use DisorderRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-01 · NCT05827159 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 3Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-08-15 · NCT06992427 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Phase 4ACL Surgery, Pain ManagementRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09 · NCT07158476 · CT.gov ↗
What to watch
2032 (1)
January 2032 (1)
Phase 1/2Chronic Lower Back Pain (CLBP)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2032-01-15 · NCT07846020 · CT.gov ↗
What to watch

See the full readout calendar ↗